Svar idag :
"Recall that we fully licensed Cevira to Asieris. Unlike our partnership with them for Hexvix in China, Asieris is solely responsible for the commercial strategy and execution behind Cevira. It is an important product for them and we are quite confident in their ability to maximize value of the asset. We are also can not comment about their product anything that they do not already disclose.
However, what I can say is that we are happy to continue to collect milestones from Asieris as the product candidate moves toward commercialization (submission and approval) and to collect sales milestones and royalties on sales without having to spend the resources to commercialize it.
Since it is not a urology product, it is non-core and that is why we licensed it out to Asieris. We are happy with our position on this case."